Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-
| Title | Journal |
|---|---|
| Anxioselective anxiolytics: on a quest for the Holy Grail. | Trends in pharmacological sciences 20121101 |
| Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. | European journal of pharmacology 20111001 |
| A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder. | CNS neuroscience & therapeutics 20100401 |
| GABA-A receptor modulators: can they offer any improvement over benzodiazepines in the treatment of anxiety disorders? | CNS neuroscience & therapeutics 20100401 |
| Pharmacological Properties of DOV 315,090, an ocinaplon metabolite. | BMC pharmacology 20080101 |
| Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination. | The Journal of pharmacology and experimental therapeutics 20060301 |
| The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. | Expert opinion on investigational drugs 20050501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040101 |
| Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. | Current drug targets. CNS and neurological disorders 20030801 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030101 |